(Conference abstract reporting NA-931s efficacy in DIO mice: ~26% weight reduction, improved lipids, no muscle loss or serious adverse effects) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference)
Texture: Lotions have a smooth, lightweight texture that is quickly absorbed into the skin, leaving a non-greasy feel
As a 2026 review noted, the original composition-of-matter patents "have likely expired reducing the commercial exclusivity that typically incentivizes industry-sponsored Phase II and III development" [13]
Each cartridge is metered into 240 increments
Diarrhea rates increase with dose: 16% at 4 mg, 22% at 8 mg, and 33-34% at 12 mg
GLP-1 helps lower blood glucose (blood sugar) by stimulating insulin release